[Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study].
We enrolled outpatients who had been newly diagnosed as hypertension or who had already taken the antihypertensive medicine in 62 medical institutions of the Toyama prefecture in the present study. Three hundred twenty-four hypertensive outpatients who were taking candesartan cilexetil(candesartan) were followed for about 12 weeks and the blood pressure(BP) lowering effect of candesartan was evaluated by self-measured home BP levels and office BP levels. Both self-measured morning and evening home BP and office BP showed a significant reduction four weeks later by administration of candesartan to the hypertensive outpatients, and this BP lowering effect was maintained until the final visit. Regardless of the mode of administration of candesartan (initial therapy to drug naive, up-titrated therapy, combination therapy with others, and switching therapy from others), BP lowering effect was shown similarly in each therapy. Because administration of candesartan at appropriate dosage (4-12 mg/day) significantly decreased self-measured morning home BP, candesartan might possess the property to maintain a sustained BP reduction for up to 24 hours after dosing, and might be able to prevent early morning cardiovascular events.
Msanobu
Takata
T
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D001713:Biphenyl Compounds; D001794:Blood Pressure; D018660:Blood Pressure Monitoring, Ambulatory; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000008:administration & dosage*; D013997:Time Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan